Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT06411639
Home Reported Outcomes in PNH
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 128
- Registration Number
- NCT06411626
- Locations
- 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
Completed
- Conditions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 602
- Registration Number
- NCT06392763
- Locations
- 🇫🇷
Novartis, Rueil-Malmaison, France
Iptacopan in Patients With ANCA Associated Vasculitis
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 78
- Registration Number
- NCT06388941
- Locations
- 🇹🇷
Novartis Investigative Site, Pendik Istanbul, Turkey
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 65
- Registration Number
- NCT06386419
- Locations
- 🇮🇳
Novartis Investigative Site, Bangalore, Karnataka, India
Modifying PEST for Psoriatic Arthritis Screening
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 502
- Registration Number
- NCT06382051
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Phase 1
Recruiting
- Conditions
- Interventions
- Drug: [68Ga]Ga-PSMA-11Drug: [68Ga]GA-DOTA-TATEDrug: [68Ga]Ga-NeoBDrug: [177Lu]Lu-PSMA-617Drug: [177Lu]Lu-DOTA-TATEDrug: [177Lu]Lu-NeoBDrug: Gonadotropin-releasing hormone (GnRH) analoguesDrug: L-Lysine HCl-L-Arginine HCl, 2.5 %,Drug: GnRH antagonistsDrug: Antiemetics & antinauseantsDrug: Metoclopramide
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT06379217
- Locations
- 🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States
🇪🇸Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT06376253
- Locations
- 🇮🇱
Novartis Investigative Site, Tel Aviv, Israel
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 318
- Registration Number
- NCT06372925
- Locations
- 🇨🇳
Novartis Investigative Site, Harbin, Heilongjiang, China
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT06345157
- Locations
- 🇮🇹
Novartis Investigative Site, Napoli, Italy
© Copyright 2024. All Rights Reserved by MedPath